Azerbaijan

Tuberculosis profile

Population 2017  9.8 million

<table>
<thead>
<tr>
<th>Estimates of TB burden*, 2017</th>
<th>Number (thousands)</th>
<th>Rate (per 100 000 population)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mortality (excludes HIV+TB)</td>
<td>0.86 (0.81–0.9)</td>
<td>8.7 (8.2–9.2)</td>
</tr>
<tr>
<td>Mortality (HIV+TB only)</td>
<td>0.023 (0.017–0.031)</td>
<td>0.24 (0.17–0.31)</td>
</tr>
<tr>
<td>Incidence (includes HIV+TB)</td>
<td>6.5 (5–8.3)</td>
<td>67 (51–84)</td>
</tr>
<tr>
<td>Incidence (HIV+TB only)</td>
<td>0.11 (0.071–0.16)</td>
<td>1.1 (0.72–1.6)</td>
</tr>
<tr>
<td>Incidence (MDR/RR-TB)**</td>
<td>1.5 (1.1–1.9)</td>
<td>15 (11–19)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Estimated TB incidence by age and sex (thousands)*, 2017</th>
</tr>
</thead>
<tbody>
<tr>
<td>0-14 years</td>
</tr>
<tr>
<td>Females</td>
</tr>
<tr>
<td>Males</td>
</tr>
<tr>
<td>Total</td>
</tr>
</tbody>
</table>

TB case notifications, 2017

- % tested with rapid diagnostics at time of diagnosis 55%
- % with known HIV status 83%
- % pulmonary 80%
- % bacteriologically confirmed among pulmonary 74%

Universal health coverage and social protection

TB treatment coverage (notified/estimated incidence), 2017  80% (63–100)

TB patients facing catastrophic total costs 0.14 (0.1–0.17)

TB/HIV care in new and relapse TB patients, 2017

Patients with known HIV-status who are HIV-positive 95%
- on antiretroviral therapy 79%

Drug-resistant TB care, 2017

Estimated MDR/RR-TB cases among notified pulmonary TB cases 1 300 (1 200–1 300)

Estimated % of TB cases with MDR/RR-TB 12% (11–14) 28% (27–30)
% notified tested for rifampicin resistance 54% 86% 4 908

Laboratory-confirmed cases MDR/RR-TB: 1 007, XDR-TB: 118

Patients started on treatment **** MDR/RR-TB: 858, XDR-TB: 182

Treatment success rate and cohort size

New cases registered in 2016 84% 1 464
Previously treated cases registered in 2016 74% 2 220
HIV-positive TB cases registered in 2016
MDR/RR-TB cases started on second-line treatment in 2015 59% 800
XDR-TB cases started on second-line treatment in 2015

TB preventive treatment, 2017

% of HIV-positive people (newly enrolled in care) on preventive treatment 52%
% of children (aged < 5) household contacts of bacteriologically-confirmed TB cases on preventive treatment 98% (72–100)

TB financing, 2018

National TB budget (US$ millions)

* Ranges represent uncertainty intervals
** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin
*** Includes cases with unknown previous TB treatment history
**** Includes patients diagnosed before 2017 and patients who were not laboratory-confirmed

Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
Generated: 2019-03-23